The transgender movement was greatly energized when The American Psychiatric Association (APA) in its 2013 revised edition of the “Diagnostic and Statistical Manual of Psychiatric Disorders” (DSM-5) delisted “Gender Identity Disorder” as a psychiatric “disorder,” reclassifying it as “Gender Dysphoria.” However, rather than providing a scientific validation of the transgender agenda, the APA’s action was a remarkable abrogation of professional responsibility in the interest of political correctness.
Unlike medical diseases, psychiatric disorders have no diagnostic biologic markers—no physical findings, laboratory tests, or imaging studies. Psychiatric diagnoses consist of symptom checklists determined by committee consensus. It should come as no surprise that the process is exquisitely reactive to prevailing cultural and political winds. Absent biomarkers that define illnesses, there is no end to the mental and emotional conditions that can be called psychiatric disorders. It can be extremely profitable for an activist special-interest movement to succeed in getting its cause legitimized as a mental disorder, not least for a pharmaceutical industry poised to retarget psychotropic drugs to treat any new mental illness.
Richard B. Corradi, Psychiatry Professor: ‘Transgenderism’ Is Mass Hysteria Similar To 1980s-Era Junk Science